The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature.

STUDY OBJECTIVES Conditions that give rise to reduced lung function are frequently associated with low-grade systemic inflammation, which may lead to poor cardiovascular outcomes. We sought to determine the relationship between reduced FEV1 and cardiovascular mortality, independent of smoking. DESIGN Longitudinal population-based study and a meta-analysis of literature. SETTING Representative sample of the general population. PARTICIPANTS Participants of the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study who were 40 to 60 years of age at baseline assessment (n = 1,861). MEASUREMENTS AND RESULTS We compared the risk of cardiovascular mortality across quintiles of FEV1. Individuals in the lowest FEV1 quintile had the highest risk of cardiovascular mortality (relative risk [RR], 3.36; 95% confidence interval [CI], 1.54 to 7.34). Compared to FEV1 quintile 1, individuals in quintile 5 had a fivefold increase in the risk of death from ischemic heart disease (RR, 5.65; 95% CI, 2.26 to 14.13). We also performed a systematic review of large cohort studies (> 500 participants) that reported on the relationship between FEV1 and cardiovascular mortality (12 studies; n = 83,880 participants). Compared to participants in the highest FEV1 category, those with reduced FEV1 had a higher risk of cardiovascular mortality (pooled RR, 1.77; 95% CI, 1.56 to 1.97). CONCLUSIONS There is strong epidemiologic evidence to indicate that reduced FEV1 is a marker for cardiovascular mortality independent of age, gender, and smoking history.

[1]  A Senthilselvan,et al.  Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis , 2004, Thorax.

[2]  Paul M. Ridker,et al.  Inflammation as a Cardiovascular Risk Factor , 2004, Circulation.

[3]  S. Kimmel,et al.  Association between pulmonary fibrosis and coronary artery disease. , 2004, Archives of internal medicine.

[4]  D. Mannino,et al.  Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. , 2003, The American journal of medicine.

[5]  D. Sin,et al.  Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. , 2003, Circulation.

[6]  A. Schols,et al.  Systemic effects in COPD. , 2002, Chest.

[7]  J. Hogg,et al.  Particulate air pollution induces progression of atherosclerosis. , 2002, Journal of the American College of Cardiology.

[8]  A. Ionescu,et al.  Inflammatory response and body composition in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[9]  B. Hedblad,et al.  Occurrence and Prognostic Significance of Ventricular Arrhythmia Is Related to Pulmonary Function: A Study From “Men Born in 1914,” Malmö, Sweden , 2001, Circulation.

[10]  C. Mulrow,et al.  Current methods of the US Preventive Services Task Force: a review of the process. , 2001, American journal of preventive medicine.

[11]  A. Folsom,et al.  Validation of death certificate diagnosis for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. , 2001, Journal of clinical epidemiology.

[12]  W Winkelstein,et al.  Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. , 2000, Chest.

[13]  David R. Jones,et al.  Empirical assessment of effect of publication bias on meta-analyses , 2000, BMJ : British Medical Journal.

[14]  H. Saito,et al.  The Relationship between Chronic Hypoxemia and Activation of the Tumor Necrosis Factor- α System in Patients with Chronic Obstructive Pulmonary Disease , 2000 .

[15]  D. Postma,et al.  Eosinophilia and positive skin tests predict cardiovascular mortality in a general population sample followed for 30 years. , 1999, American journal of epidemiology.

[16]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[17]  Daniel Levy,et al.  Accuracy of Death Certificates for Coding Coronary Heart Disease as the Cause of Death , 1998, Annals of Internal Medicine.

[18]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[19]  J. Fujita,et al.  Measurement of hepatocyte growth factor in serum and bronchoalveolar lavage fluid in patients with pulmonary fibrosis. , 1998, Respiratory medicine.

[20]  J. Feldman,et al.  Plan and operation of the NHANES I Epidemiologic Followup Study, 1992. , 1997, Vital and health statistics. Ser. 1, Programs and collection procedures.

[21]  V M Hawthorne,et al.  Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study , 1996, BMJ.

[22]  T Nakamura,et al.  The hepatocyte growth factor regulates the synthesis of acute‐phase proteins in human hepatocytes: Divergent effect on interleukin‐6‐stimulated genes , 1996, Hepatology.

[23]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[24]  D. Strachan.  Ventilatory function, height, and mortality among lifelong non-smokers. , 1992, Journal of epidemiology and community health.

[25]  P. Schnohr,et al.  Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. , 1991, The European respiratory journal.

[26]  M. Lebowitz,et al.  Death certificate reporting of confirmed airways obstructive disease. , 1991, American journal of epidemiology.

[27]  D. Reed,et al.  Smoking, pulmonary function, and mortality. , 1990, Annals of epidemiology.

[28]  G. Comstock,et al.  Respiratory risk factors and mortality: longitudinal studies in Washington County, Maryland. , 1989, The American review of respiratory disease.

[29]  D. Dockery,et al.  Chronic obstructive pulmonary disease mortality in six U.S. cities. , 1989, The American review of respiratory disease.

[30]  L. Kuller,et al.  The epidemiology of pulmonary function and COPD mortality in the multiple risk factor intervention trial. , 1989, The American review of respiratory disease.

[31]  D. Reed,et al.  Pulmonary function as a predictor of coronary heart disease. , 1989, American journal of epidemiology.

[32]  K L Ebi-Kryston,et al.  Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study. , 1988, Journal of clinical epidemiology.

[33]  M. Wysocki,et al.  The relation of thirteen-year mortality to ventilatory impairment and other respiratory symptoms: the Cracow Study. , 1986, International journal of epidemiology.

[34]  T. Beaty,et al.  Effects of pulmonary function on mortality. , 1985, Journal of chronic diseases.

[35]  Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. , 1982, JAMA.

[36]  M. Higgins,et al.  Predictors of mortality in the adult population of Tecumseh. , 1970, Archives of environmental health.